Vicarious Surgical Announces President Transition to Board Member Role

$RBOT
Industrial Specialties
Health Care
Get the next $RBOT alert in real time by email

Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that Company President, Randy Clark, will transition to Board Member, effective April 25, 2025, pending customary conflict checks.

As President, Mr. Clark directed critical business functions, including product development, operations, clinical regulatory, quality affairs, and human resources. He spearheaded the strategic development of Vicarious Surgical's manufacturing capabilities, establishing key partnerships and strengthening the supply chain. Notably, he implemented key personnel realignment, streamlined business processes, and formalized workflows and standardized procedures in order to position the Company for its next phase of growth.

"Under Randy's leadership as President, Vicarious Surgical has made significant strides in building a strong foundation for future growth," said Adam Sachs, Co-founder and Chief Executive Officer. "We are incredibly grateful for his dedication and are delighted that he will continue to contribute his invaluable expertise and strategic vision as a member of our Board of Directors. This transition allows us to retain his insights while evolving our leadership structure to best serve the Company's strategic and capital needs."

Mr. Clark stated, "I want to express my sincere gratitude to the Vicarious Surgical team and Board. I am incredibly proud of what we have accomplished together, and for that, Vicarious Surgical is now exceptionally well-positioned to execute its strategy and achieve its milestones. It's precisely because of this strong foundation that I feel comfortable transitioning to a new role, knowing I'll remain a part of the Vicarious Surgical journey, supporting the Company in a different capacity as we move forward."

About Vicarious Surgical

Founded in 2014, Vicarious Surgical is a next-generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company's novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla's Khosla Ventures, Innovation Endeavors, Jerry Yang's AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang's E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Vicarious Surgical's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of Vicarious Surgical's Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of Vicarious Surgical's initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of Vicarious Surgical to raise financing in the future; the success, cost and timing of Vicarious Surgical's product and service development activities; the potential attributes and benefits of Vicarious Surgical's product candidates and services; Vicarious Surgical's ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; Vicarious Surgical's ability to identify, in-license or acquire additional technology; Vicarious Surgical's ability to maintain its existing license, manufacture, supply and distribution agreements; Vicarious Surgical's ability to compete with other companies currently marketing or engaged in the development of products and services that Vicarious Surgical is currently marketing or developing; the size and growth potential of the markets for Vicarious Surgical's product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Vicarious Surgical's product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; Vicarious Surgical's financial performance; economic downturns, political and market conditions and their potential to adversely affect Vicarious Surgical's business, financial condition and results of operations; Vicarious Surgical's intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in Vicarious Surgical's filings with the SEC. Vicarious Surgical cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vicarious Surgical does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Investor Contact

Kaitlyn Brosco

Vicarious Surgical

Kbrosco@vicarioussurgical.com



Media Inquiries

media@vicarioussurgical.com

Get the next $RBOT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RBOT

DatePrice TargetRatingAnalyst
3/4/2022$16.00 → $7.00Overweight → Neutral
Piper Sandler
1/7/2022$16.00Outperform
Credit Suisse
12/7/2021$15.00Outperform
Cowen & Co.
11/5/2021$15.00Buy
Canaccord Genuity
10/18/2021$15.00Buy
BTIG
10/7/2021$16.00Overweight
Piper Sandler
More analyst ratings

$RBOT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Vicarious Surgical Receives Continued Listing Standard Notice from the NYSE

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on April 10, 2025, the Company received written notice (the "Notice") from the New York Stock Exchange (the "NYSE") indicating that the Company is no longer in compliance with the continued listing standards set forth under Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, the Company's last reported stockholders' equity was les

    $RBOT
    Industrial Specialties
    Health Care
  • Vicarious Surgical Announces President Transition to Board Member Role

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that Company President, Randy Clark, will transition to Board Member, effective April 25, 2025, pending customary conflict checks. As President, Mr. Clark directed critical business functions, including product development, operations, clinical regulatory, quality affairs, and human resources. He spearheaded the strategic development of Vicarious Surgical's manufacturing capabilities, establishing key partnerships and strengthening the supply chain. Notably, he implemented key personnel

    $RBOT
    Industrial Specialties
    Health Care
  • Vicarious Surgical Reports Fourth Quarter and Full Year 2024 Financial Results

    Version 1.0 System Integration Complete; Progressing Towards First Clinical Use Achieved 2024 Cash Burn Guidance; Sets 2025 Cash Burn Guidance of $50 Million Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter and full year ended December 31, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, March 17, 2025. "2024 was a pivotal year of progress for Vicarious Surgical, as we expanded our strategic hospital partnerships with LSU Health New Orleans, Temple Health, and Univers

    $RBOT
    Industrial Specialties
    Health Care

$RBOT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RBOT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RBOT
SEC Filings

See more

$RBOT
Leadership Updates

Live Leadership Updates

See more
  • Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer

    Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Sarah Romano as Chief Financial Officer (CFO), effective April 1, 2025. Ms. Romano will oversee Vicarious Surgical's financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the h

    $RBOT
    Industrial Specialties
    Health Care
  • Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0 System ("V1.0"), the newly established role of President is designed to fortify organizational alignment and focus on the Company's long-term needs and objectives. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will a

    $RBOT
    Industrial Specialties
    Health Care
  • Vicarious Surgical Announces Changes to Board of Directors

    Victoria Carr-Brendel, Ph.D. Elected to Board of Directors Tech-Focused Venture Capitalist Phil Liang to Resign Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company"), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced the appointment of Victoria Carr-Brendel, Ph.D. to the Vicarious Surgical Board of Directors effective today, January 23, 2023. The Company also announced the resignation of technology-focused venture capitalist Phil Liang from the Vicarious Surgical Board of Directors effective as of today. "On behalf of the board, I'd like to thank Phil for his critical guidance and expertise as Vicari

    $RBOT
    Industrial Specialties
    Health Care

$RBOT
Financials

Live finance-specific insights

See more
  • Vicarious Surgical Reports Fourth Quarter and Full Year 2024 Financial Results

    Version 1.0 System Integration Complete; Progressing Towards First Clinical Use Achieved 2024 Cash Burn Guidance; Sets 2025 Cash Burn Guidance of $50 Million Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter and full year ended December 31, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, March 17, 2025. "2024 was a pivotal year of progress for Vicarious Surgical, as we expanded our strategic hospital partnerships with LSU Health New Orleans, Temple Health, and Univers

    $RBOT
    Industrial Specialties
    Health Care
  • Vicarious Surgical to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 17, 2025

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the fourth quarter and fiscal year ended December 31, 2024 after the market closes on Monday, March 17, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 373279. A live and archived webcast of the event will be availabl

    $RBOT
    Industrial Specialties
    Health Care
  • Vicarious Surgical Reports Third Quarter 2024 Financial Results

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter ended September 30, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, November 12, 2024. "Our team's strong execution throughout the year, continuing in the third quarter, has us on track to achieve our Version 1.0 System integration milestone within the next few weeks," said Adam Sachs, Co-Founder and Chief Executive Officer. "This sets the stage for us to complete our first clinical patient in less than a year, a criti

    $RBOT
    Industrial Specialties
    Health Care

$RBOT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more